# Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

> **NCT00920205** · PHASE1 · COMPLETED · sponsor: **Myrexis Inc.** · enrollment: 26 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** MPC-3100 (an Hsp90 inhibitor)

## Key facts

- **NCT ID:** NCT00920205
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920205, "Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00920205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*